PTC Therapeutics (PTCT) Stock Forecast & Price Target

Compare

405 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTCT Analyst Ratings

Moderate Buy

8 Buy

5 Hold

1 Sell

Based on 14 analysts giving stock ratings to

PTC

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTCT Stock 12 Month Forecast

Average Price Target

$77.20

▼(-0.08% Downside)

Based on 14 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $77.20 with a high forecast of $118.00 and a low forecast of $54.00. The average price target represents a -0.08% change from the last price of $77.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","119":"$119","62.75":"$62.8","81.5":"$81.5","100.25":"$100.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$118.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,62.75,81.5,100.25,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.2,82.18461538461538,85.16923076923077,88.15384615384616,91.13846153846154,94.12307692307692,97.1076923076923,100.09230769230768,103.07692307692308,106.06153846153846,109.04615384615384,112.03076923076924,115.01538461538462,{"y":118,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.2,79.04615384615384,78.8923076923077,78.73846153846154,78.58461538461539,78.43076923076923,78.27692307692308,78.12307692307692,77.96923076923078,77.81538461538462,77.66153846153847,77.50769230769231,77.35384615384616,{"y":77.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.2,77.26153846153846,75.32307692307693,73.38461538461539,71.44615384615385,69.50769230769231,67.56923076923077,65.63076923076923,63.69230769230769,61.753846153846155,59.815384615384616,57.87692307692308,55.93846153846154,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.43,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$118.00

Average Price Target$77.20

Lowest Price Target$54.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joon Lee

Truist Financial

―

Buy

―

Reiterated

12/03/25

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR), PTC Therapeutics (NASDAQ: PTCT) and Bristol-Myers Squibb (NYSE: BMY)

Sami Corwin

William Blair

―

Buy

―

Reiterated

12/03/25

PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch

Tiago Fauth

Wells Fargo

$93

Buy

20.37%

Upside

Reiterated

12/03/25

PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo

Paul Choi

Goldman Sachs

$50→$55

Sell

-28.81%

Downside

Reiterated

12/03/25

PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

12/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (NASDAQ: PTCT), ALX Oncology Holdings (NASDAQ: ALXO) and Encompass Health (NYSE: EHC)

Brian Abrahams

RBC Capital

$82→$91

Hold

17.78%

Upside

Downgraded

12/01/25

PTC Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalPTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Kristen Kluska

Cantor Fitzgerald

$118

Buy

52.73%

Upside

Reiterated

11/18/25

PTC Therapeutics (PTCT) Receives a Buy from Cantor Fitzgerald

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

11/11/25

Strong Market Penetration and Strategic Pricing Propel PTC Therapeutics to a Buy Rating

Geoff Meacham

Citi

$50→$75

Hold

-2.93%

Downside

Reiterated

11/05/25

PTC Therapeutics price target raised to $75 from $50 at CitiPTC Therapeutics price target raised to $75 from $50 at Citi

Judah Frommer

Morgan Stanley

$71→$78

Buy

0.96%

Upside

Reiterated

11/05/25

PTC Therapeutics (PTCT) Receives a Buy from Morgan StanleyWe take our 12‐month price target to $78 (from $71).

Gena Wang

Barclays

$46→$68

Hold

-11.99%

Downside

Reiterated

11/05/25

PTC Therapeutics price target raised to $68 from $46 at BarclaysPTC Therapeutics price target raised to $68 from $46 at Barclays

Joseph Thome

TD Cowen

$50→$63

Hold

-18.46%

Downside

Reiterated

11/04/25

PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts3:52 AM PTC Therapeutics (NASDAQ: PTCT) Hold (2) ESG $63.00 (Prior $50.00) In PKU View Full Report THE TD COWEN INSIGHT Initial Sephience sales of $19.2MM beat the $4MM consensus, and surpassed the higher end of investor expectations. There were 521 U.S. patient start forms with 341 total patients on commercial therapy WW, across the spectrum of treatment history and severity. PTC anticipates that the momentum will continue, thus we updated our launch estimates which increases our SOTP-based PT to $63/share. Expectations PTC reported $19.2MM in Sephience sales, substantially beating the $4MM consensus.

Kelly Shi

Jefferies

$63→$77

Buy

-0.34%

Downside

Reiterated

10/28/25

PTC Therapeutics price target raised to $77 from $63 at JefferiesPTC Therapeutics price target raised to $77 from $63 at Jefferies

Joseph Schwartz

Leerink Partners

$54

Hold

-30.11%

Downside

Reiterated

10/16/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Eliana Merle

UBS

$80

Buy

3.55%

Upside

Reiterated

09/03/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joon Lee

Truist Financial

―

Buy

―

Reiterated

12/03/25

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR), PTC Therapeutics (NASDAQ: PTCT) and Bristol-Myers Squibb (NYSE: BMY)

Sami Corwin

William Blair

―

Buy

―

Reiterated

12/03/25

PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch

Tiago Fauth

Wells Fargo

$93

Buy

20.37%

Upside

Reiterated

12/03/25

PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo

Paul Choi

Goldman Sachs

$50→$55

Sell

-28.81%

Downside

Reiterated

12/03/25

PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

12/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (NASDAQ: PTCT), ALX Oncology Holdings (NASDAQ: ALXO) and Encompass Health (NYSE: EHC)

Brian Abrahams

RBC Capital

$82→$91

Hold

17.78%

Upside

Downgraded

12/01/25

PTC Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalPTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Kristen Kluska

Cantor Fitzgerald

$118

Buy

52.73%

Upside

Reiterated

11/18/25

PTC Therapeutics (PTCT) Receives a Buy from Cantor Fitzgerald

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

11/11/25

Strong Market Penetration and Strategic Pricing Propel PTC Therapeutics to a Buy Rating

Geoff Meacham

Citi

$50→$75

Hold

-2.93%

Downside

Reiterated

11/05/25

PTC Therapeutics price target raised to $75 from $50 at CitiPTC Therapeutics price target raised to $75 from $50 at Citi

Judah Frommer

Morgan Stanley

$71→$78

Buy

0.96%

Upside

Reiterated

11/05/25

PTC Therapeutics (PTCT) Receives a Buy from Morgan StanleyWe take our 12‐month price target to $78 (from $71).

Gena Wang

Barclays

$46→$68

Hold

-11.99%

Downside

Reiterated

11/05/25

PTC Therapeutics price target raised to $68 from $46 at BarclaysPTC Therapeutics price target raised to $68 from $46 at Barclays

Joseph Thome

TD Cowen

$50→$63

Hold

-18.46%

Downside

Reiterated

11/04/25

Kelly Shi

Jefferies

$63→$77

Buy

-0.34%

Downside

Reiterated

10/28/25

PTC Therapeutics price target raised to $77 from $63 at JefferiesPTC Therapeutics price target raised to $77 from $63 at Jefferies

Joseph Schwartz

Leerink Partners

$54

Hold

-30.11%

Downside

Reiterated

10/16/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Eliana Merle

UBS

$80

Buy

3.55%

Upside

Reiterated

09/03/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PTC Therapeutics

1 Month

xxx

Success Rate

13/17 ratings generated profit

Average Return

+7.93%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.47% of your transactions generating a profit, with an average return of +7.93% per trade.

3 Months

xxx

Success Rate

13/16 ratings generated profit

Average Return

+15.57%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +15.57% per trade.

1 Year

Tiago FauthWells Fargo

Success Rate

16/16 ratings generated profit

Average Return

+58.45%

reiterated a buy rating 5 days ago

Copying Tiago Fauth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +58.45% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+99.34%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +99.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTCT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTCT has received 23 Buy Ratings, 8 Hold Ratings, and 2 Sell Ratings. PTCT average Analyst price target in the past 3 months is 77.20.

Each month's total comprises the sum of three months' worth of ratings.

PTCT Financial Forecast

PTCT Earnings Forecast

Next quarter’s earnings estimate for PTCT is -$0.47 with a range of -$1.84 to $1.24. The previous quarter’s EPS was $0.20. PTCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PTCT has Performed in-line its overall industry.

PTCT Sales Forecast

Next quarter’s sales forecast for PTCT is $236.17M with a range of $167.67M to $385.47M. The previous quarter’s sales results were $211.01M. PTCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PTCT has Performed in-line its overall industry.

PTCT Stock Forecast FAQ

What is PTCT’s average 12-month price target, according to analysts?

Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 77.20.

What is PTCT’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for PTCT, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTCT a Buy, Sell or Hold?

PTC Therapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 1 sell ratings.

What is PTC Therapeutics’s price target?

The average price target for PTC Therapeutics is 77.20. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $118.00 ,the lowest forecast is $54.00. The average price target represents -0.08% Decrease from the current price of $77.26.

What do analysts say about PTC Therapeutics?

PTC Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of PTCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTCT Analyst Ratings

PTCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering PTC Therapeutics

PTCT Analyst Recommendation Trends

PTCT Financial Forecast

PTCT Earnings Forecast

PTCT Sales Forecast

PTCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts